Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc.

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Vaxart, Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies utilizing the Medici Drug Delivery System™ for the prevention and management of serious chronic diseases. The company focuses on diseases that are prevalent, poorly controlled, and growing at an epidemic rate, with a dual focus on preventive and therapeutic medicine.

Intarcia Therapeutics, Inc.

NellOne Therapeutics is an early stage biopharmaceutical company focused on advances in regenerative medicine using the NELL1 protein for tissue repair.

NellOne Therapeutics

Sutro Biopharma, Inc. is a biotechnology company focused on clinical stage drug discovery, development, and manufacturing. The company specializes in precisely designed cancer therapeutics, as self-described.

Metric
Company Name	Sutro Biopharma, Inc.	Vaxart, Inc.	Intarcia Therapeutics, Inc.	NellOne Therapeutics
Symbol	STRO	VXRT
MSH ID	COM:SUTROBIO	COM:VAXART	COM:INTARCIA	COM:NELL-ONE
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biopharmaceuticals	Biotechnology
Country	US	US		US
Stage	Post-IPO Equity
Employee Count	300	109	251
Website	sutrobio.com	vaxart.com	intarcia.com	nell-one.com
LinkedIn
Founders

Metric
Market Cap	294.46M	149.96M
Enterprise Value
Monthly Web Traffic	9.82K
Web Traffic Growth	0.04
Valuation
Raised Capital	75M

Metric
Revenue	153.73M	7.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit	146.91M	2.88M
EBITDA	-82.46M	-78.85M
Operating Income	-89.28M	-83.35M
Net Income	-106.79M	-82.47M
EPS	-1.78	-0.57
Diluted EPS	-1.78	-0.57
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.96	1
Operating Profit Margin	-0.58	-6.11
EBITDA Margin	-0.54	-10.69
Net Profit Margin	-0.69	-6.16
Return on Equity	-0.71	-0.75
Return on Assets	-0.23	-0.62
Return on Capital Employed	-0.24	-0.77

COM:SUTROBIO

Sutro Biopharma, Inc.

Last Close

2.53

22/11 21:00

Market Cap

294.46M

Beta: -

Volume Today

843.86K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.56	-1.96
P/B Ratio	2.42	2.44
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.33	83.77
EV Multiple	-1.22	-0.06

Metric
Days Sales Outstanding	124.77	61.88
Days Payables Outstanding
Days Inventory Outstanding	0.00	0.00
Operating Cycle	124.77	191.81
Cash Conversion Cycle	-111.15	66.23
Asset Turnover	0.38	0.11

Metric
Operating Cash Flow	-111.62M	-70.45M
Free Cash Flow	-115.93M	-72.32M
Cash Flow to Debt	-0.44	-2.91
Operating Cash Flow/Sales	-0.44	-5.03
Free Cash Flow Yield	-0.57	-0.47

Metric
Cash & Equivalents	69.27M	34.76M
Accounts Receivable	-28.96M	-2.99M
Inventory
Goodwill		4.51M
Debt to Capitalization	0.62	0.22
Debt to Assets	0.09	0.19
Current Ratio	5.18	5.07
Quick Ratio	5.05	4.67

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.50	5.52
R&D to Revenue	3.49	29.55
SG&A to Revenue	1.24	9.43